19153941

Source:http://linkedlifedata.com/resource/pubmed/id/19153941

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0001554, umls-concept:C0008976, umls-concept:C0018896, umls-concept:C0036341, umls-concept:C0171023, umls-concept:C0289313, umls-concept:C0473169, umls-concept:C1513158
pubmed:issue	1
pubmed:dateCreated	2009-1-20
pubmed:abstractText	Excessive body weight gain (BWG), hyperglycemia and dyslipidemia are important side effects of olanzapine. We assessed the effects of rosiglitazone on BWG, the insulin resistance index (HOMA-IR), lipids, glycated hemoglobin and fibrinogen in olanzapine-treated schizophrenia patients.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8402938
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antipsychotic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Benzodiazepines, http://linkedlifedata.com/resource/pubmed/chemical/Fibrinogen, http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobins, http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Thiazolidinediones, http://linkedlifedata.com/resource/pubmed/chemical/olanzapine, http://linkedlifedata.com/resource/pubmed/chemical/rosiglitazone
pubmed:status	MEDLINE
pubmed:month	Jan
pubmed:issn	0176-3679
pubmed:author	pubmed-author:Araujo de BaptistaEE, pubmed-author:BaptistePP, pubmed-author:BeaulieuSS, pubmed-author:El FakihYY, pubmed-author:GaleazziTT, pubmed-author:RangelNN, pubmed-author:UzcáteguiEE
pubmed:issnType	Print
pubmed:volume	42
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	14-9
pubmed:meshHeading	pubmed-meshheading:19153941-Adult, pubmed-meshheading:19153941-Antipsychotic Agents, pubmed-meshheading:19153941-Benzodiazepines, pubmed-meshheading:19153941-Body Mass Index, pubmed-meshheading:19153941-Body Weight, pubmed-meshheading:19153941-Double-Blind Method, pubmed-meshheading:19153941-Female, pubmed-meshheading:19153941-Fibrinogen, pubmed-meshheading:19153941-Hemoglobins, pubmed-meshheading:19153941-Humans, pubmed-meshheading:19153941-Hypoglycemic Agents, pubmed-meshheading:19153941-Insulin Resistance, pubmed-meshheading:19153941-Lipid Metabolism, pubmed-meshheading:19153941-Male, pubmed-meshheading:19153941-Metabolic Diseases, pubmed-meshheading:19153941-Middle Aged, pubmed-meshheading:19153941-Pilot Projects, pubmed-meshheading:19153941-Schizophrenia, pubmed-meshheading:19153941-Statistics as Topic, pubmed-meshheading:19153941-Thiazolidinediones
pubmed:year	2009
pubmed:articleTitle	Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.
pubmed:affiliation	Department of Physiology, Los Andes University Medical School, Mérida, Venezuela. trinbap@yahoo.com
pubmed:publicationType	Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't